News - Protalix BioTherapeutics


Current filters:

Protalix BioTherapeutics

Popular Filters

Pfizer and Protalix' Gaucher drug Uplyso approved in Brazil


US drugs behemoth Pfizer (NYSE: PFE) and Israel-based Protalix BioTherapeutics (NYSE MKT:PLX) said that…

BiotechnologyElelysoPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationSouth AmericaUplyso

Protalix and Pfizer expand Elelyso agreement


Israeli drug developer Protalix BioTherapeutics (NYSE-AMEX: OLX) said yesterday that it has entered into…

ElelysoLicensingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesResearch

Pfizer 3rd-qtr profits slump on lower than expected sales; EU says "no" to Gaucher drug


US pharma behemoth Pfizer (NYSE: PFE) saw it shares fall 1.1% to $24.59 in morning trading yesterday,…

EuropeFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

Protalix gains Israeli approval for Gaucher drug Elelyso


ael-based Protalix BioTherapeutics (NYSE-AMEX: OLX) has received marketing authorization from the Israeli…

BiotechnologyElelysoPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationRest of the World

$25 million milestone for Protalix following US approval of Elelyso


Israel-based Protalix BioTherapeutics (TASE:PLX) has received a $25 million milestone payment from global…

ElelysoFinancialPfizerPharmaceuticalProtalix BioTherapeuticsRare diseases

Elelyso: a new therapeutic option for patients with Gaucher disease


The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Pfizer's Elelyso approved in USA for Gaucher disease; Celebrex settlement


The US Food and Drug Administration yesterday approved Elelyso (taliglucerase alfa) for injection, an…

Anti-Arthritics/RheumaticsCelebrexElelysoLegalNorth AmericaPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

Protalix submits CRL reply to FDA on Gaucher drug taliglucerase; reports new trial data


USA-based Protalix BioTherapeutics (NYSE-AMEX: PLX) says it has submitted its reply to the Complete Response…

North AmericaPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesRegulationtaliglucerase

Back to top